AERI announced positive results from a phase III study (Rocket 2) on Rhopressa, which is being evaluated for its ability in lowering intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Aerie Pharmaceuticals Inc. shares jumped the most ever after the company’s experimental drug Rhopressa eased glaucoma-associated eye pressure in a final-stage trial. For these stocks with recent usually high volume, the overall technical picture will be used to help gauge in which direction the next tradable moves will be. Aerie recently completed its first Phase 3 registration trial, named Rocket 1, the three-month efficacy results of which were initially reported in April 2015, and expects to commence a fourth Phase 3 registration trial, named Rocket 4, in late September 2015. The company has a 52-week high of $35.8899. The stock had previously closed at $18.00. RBC Capital upped their price target on Aerie Pharmaceuticals from $31.00 to $44.00 and gave the company an “outperform” rating in a research note on Thursday. Today, you can download 7 Best Stocks for the Next 30 Days. 4 analysts rated the company as a strong buy.
TheStreet lowered shares of Supercom (NASDAQ:SPCB) from a buy rating to a hold rating in a research note released on Wednesday morning, AnalystRatings.Net reports. Dafna Capital Management Llc is another bull as the active investment manager who is having 156,842 shares of Aerie Pharmaceuticals or 2.34% of their USA long equity exposure.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Wednesday, August 5th. The high patient dropout rate of 40% was quickly flagged by analysts on Twitter and won’t be ignored by payers if Aerie remains on track to a 2017 market launch. (NASDAQ:AERI) at 1.33. Research Analysts at Zacks have ranked the company at 2, suggesting the traders with a rating of buy for the short term. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company has a market cap of $453 million and there are 25,692,000 shares in outstanding.
Aerie’s other leading product Roclatan is a combination of the triple-action compound Rhopressa, formulated with latanoprost in a single eye drop. The firm believes that the data provided by the company is sufficient to eliminate all the risk faced by the clinical program. Although the company seems to be successfully transitioning into a cloud-based infrastructure, the figures in the report revealed it has been hit hard by the strengthening US dollar.